Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Nervous System Neoplasms » Central Nervous System Neoplasms
Diseases [C] » Nervous System Diseases [C10] » Nervous System Neoplasms » Central Nervous System Neoplasms
Description
Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges. MeSH
Hierarchy View
Subtype Terms (4)
Brain Neoplasms
524 drugs (253 approved, 271 experimental)
Meningeal Neoplasms
8 drugs (5 approved, 3 experimental)
Spinal Cord Neoplasms
15 drugs (10 approved, 5 experimental)
Phase 3 Indicated Drugs (15)
Phase 2 Indicated Drugs (20)
Phase 1 Indicated Drugs (26)
Other Experimental Indicated Drugs (3)
Organization Involved with Phase 4 Indications (3)
Organization Involved with Phase 3 Indications (59)
Case Western Reserve University
Children's Cancer and Leukaemia Group
Children's National Medical Center
Cooperative Trials Group for Neuro-Oncology
Eastern Cooperative Oncology Group
European Organisation for Research and Treatment of Cancer
Florida International University
Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany
Icahn School of Medicine at Mount Sinai
Katholieke Universiteit Leuven
National Cancer Institute (NCI)
North Central Cancer Treatment Group
The Christie NHS Foundation Trust
The Pacific Pediatric Neuro-Oncology Consortium
The University of Texas, Dallas
Trans Tasman Radiation Oncology Group
Organization Involved with Phase 2 Indications (102)
Hoag Memorial Hospital Presbyterian
Italian Association for Pediatric Hematology Oncology
Korea Research Institute of Bioscience & Biotechnology
Ligue contre le cancer, France
Moorgreen Hospital, Southampton
National Cancer Institute, France
National Institutes of Health (NIH)
National Natural Science Foundation of China
Pediatric Brain Tumor Consortium
Royal Liverpool & Broadgreen University Hospitals NHS Truts
Royal Marsden Hospital NHS Trust
San Diego Pacific Oncology & Hematology Associates
Translational Research Informatics Center, Kobe, Hyogo, Japan
Organization Involved with Phase 1 Indications (36)
Organization Involved with Other Experimental Indications (8)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
